Advertisement

Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications

      Abstract

      Purpose

      This analysis aimed to identify all strong drug-drug interactions (DDIs) associated with drugs approved by the US Food and Drug Administration (FDA) in 2021.

      Methods

      DDI data for small molecular drugs approved by the FDA in 2021 (N = 36) were analyzed using the University of Washington Drug Interaction Database. The mechanism(s) and clinical magnitude of these interactions were characterized based on information available in the new drug application reviews. Clinical studies and simulation results with mean AUC ratios (AUCRs) ≥5 for inhibition DDIs and ≤0.2 for induction (ie, strong interactions) were then fully analyzed. A total of 7 drugs had an AUC change ≥5-fold as victim drugs, with inhibition and induction of cytochrome P450 (CYP) 3A explaining all interactions.

      Findings

      Six drugs, namely atogepant, finerenone, ibrexafungerp, infigratinib, mobocertinib, and voclosporin, were sensitive substrates of CYP3A, with AUCRs of 5.45 to 18.55 when co-administered with the strong inhibitors itraconazole or ketoconazole, whereas avacopan was a moderate sensitive substrate of CYP3A, most sensitive to induction (>5-fold change). Only 1 drug, viloxazine, was a strong perpetrator (CYP1A2 inhibition with caffeine AUCR of 5.83). No drug had strong inhibition of transporters and no strong induction of enzymes or transporters was detected. No dominant therapeutic class was identified. As expected, all these strong DDIs triggered strict labeling recommendations.

      Implications

      Overall, identifying strong DDIs with newly approved drugs and understanding their mechanisms are critical to provide effective management strategies in patients who often receive multiple comedications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • FDA
        Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions.
        FDA Guid. 2020; 1: 1-27
      1. Abbvie. QULIPTA (atogepant) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215206Orig1s000TOC.cfm. Accessed July 20, 2022.

      2. ChemoCentryx. TAVNEOS (avacopan) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000TOC.cfm. Accessed July 20, 2022.

      3. Bayer HealthCare. Pharmaceuticals. KERENDIA (finerenone) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215341Orig1s000TOC.cfm. Accessed July 20, 2022.

        • Heinig R
        • Gerisch M
        • Engelen A
        • et al.
        Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo.
        Eur J Drug Metab Pharmacokinet. 2018; 43: 715-727https://doi.org/10.1007/s13318-018-0483-9
      4. Scynexis. BREXAFEMME (ibrexafungerp) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000TOC.cfm. Accessed July 20, 2022.

      5. QED Therapeutics. TRUSELTIQ (infigratinib) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214622Orig1s000TOC.cfm. Accessed July 20, 2022.

      6. Takeda Pharmaceuticals USA. EXKIVITY (mobocertinib) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000TOC.cfm. Accessed July 20, 2022.

      7. Supernus Pharmaceuticals. QELBREE (viloxazine) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000TOC.cfm. Accessed July 20, 2022.

      8. Aurinia Pharmaceuticals. LUPKYNIS (voclosporin) product label and NDA reviews. Published online 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213716Orig1s000TOC.cfm. Accessed July 20, 2022.

        • Yu J
        • Wang Y
        • Ragueneau-Majlessi I.
        Pharmacokinetic drug-drug interactions with drugs approved by the US Food and Drug Administration in 2020: mechanistic understanding and clinical recommendations.
        Drug Metab Dispos. 2021; 47: 135-144https://doi.org/10.1124/dmd.121.000401
        • Yu J
        • Petrie ID
        • Levy RH
        • et al.
        Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017.
        Drug Metab Dispos. 2019; 47: 135-144https://doi.org/10.1124/dmd.118.084905
        • Yu J
        • Ritchie T.K
        • Mulgaonkar A
        • et al.
        Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.
        Drug Metab Dispos. 2014; 42: 1991-2001https://doi.org/10.1124/dmd.114.060392
        • Yu J
        • Zhou Z
        • Tay-Sontheimer J
        Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016.
        Drug Metab Dispos. 2018; 46: 835-845https://doi.org/10.1124/dmd.117.078691